The Oral Administration of Sanguisorba officinalis Extract Improves Physical Performance through LDHA Modulation

Han, Jung Ho; Kim, Minjeong; Choi, Hee-Jin; Jin, Jong Sook; Lee, Syng‐Ook; Bae, Sung-Jin; Ryu, Dongryeol; Ha, Ki‐Tae

doi:10.3390/molecules26061579

Cited by 6 publications

(4 citation statements)

References 78 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, PDK inhibition has been demonstrated to reduce cancer cell growth and enhance susceptibility to chemotherapy [12]. Lactate dehydrogenase (LDH) regulates the conversion and production of pyruvate and lactic acid [13]. Inhibition of LDH A (LDHA) increases oxidative stress and reduces chemoresistance [14].…”

Section: Introductionmentioning

confidence: 99%

Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Park,

Han,

Wei

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Targeted therapy against the epidermal growth factor receptor (EGFR) is a promising treatment approach for NSCLC. However, resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a major challenge in its clinical management. EGFR mutation elevates the expression of hypoxia-inducible factor-1 alpha to upregulate the production of glycolytic enzymes, increasing glycolysis and tumor resistance. The inhibition of glycolysis can be a potential strategy for overcoming EGFR-TKI resistance and enhancing the effectiveness of EGFR-TKIs. In this review, we specifically explored the effectiveness of pyruvate dehydrogenase kinase inhibitors and lactate dehydrogenase A inhibitors in combating EGFR-TKI resistance. The aim was to summarize the effects of these natural products in preclinical NSCLC models to provide a comprehensive understanding of the potential therapeutic effects. The study findings suggest that natural products can be promising inhibitors of glycolytic enzymes for the treatment of EGFR-TKI-resistant NSCLC. Further investigations through preclinical and clinical studies are required to validate the efficacy of natural product-based glycolytic inhibitors as innovative therapeutic modalities for NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Park,

Han,

Wei

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sanguisorba officinalis L., a member of the Rosaceae family, is an important edible plant whose root is also employed in herbal medicine (Han et al, 2021). S. officinalis L. is a traditional Chinese medicine used to treat skin injuries in China.…”

Section: Introductionmentioning

confidence: 99%

“…Through inhibiting NLRP3 inflammasome activation with Bletilla striata polysaccharide, Zhao et al (2021) promote DW healing. Sanguisorba officinalis L., a member of the Rosaceae family, is an important edible plant whose root is also employed in herbal medicine (Han et al, 2021). S. officinalis L. is a traditional Chinese medicine used to treat skin injuries in China.…”

Section: Introductionmentioning

confidence: 99%

Sanguisorba officinalis L. promotes diabetic wound healing in rats through inflammation response mediated by macrophage

Song

Zeng

Zheng

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Sanguisorba officinalis L., a traditional Chinese medicine, is frequently used to treat burns and scalds. But even so, it is unknown whether S. officinalis L. can accelerate diabetic wounds (DW) healing. Here, to bridge the gap, we employed in vivo and in vitro evaluations to assess the positive effect of S. officinalis L. ethanol extract (ESO) on DW. Results demonstrated that ESO dramatically improved the DW healing rate. With ESO treatment, the inappropriately elevated levels of IL6, IL1β and TNFα in DW were reduced, while the expression of IL10 was increased, indicating that the abnormal inflammation in DW was also under control. Moreover, the abnormally elevated expression of CD86 was significantly inhibited and the expression of CD206 was significantly up‐regulated following treatment with ESO. The global level of NF‐κB protein was not affected by ESO treatment, but it suppressed the expression of phosphorylated NF‐κB and prevented its nuclear entry. In addition, in RAW264.7 cells activated with lipopolysaccharide (LPS), the expression of NLRP3, Caspase1 and IL1β were significantly diminished following ESO treatment. In conclusion, ESO was proved to be a promising treatment for DW healing due to its potential to accelerate the healing process by suppressing the inflammatory response. This was achieved by increasing the ratio of M2 to M1 polarization through blocking the NF‐κB/NLRP3 signaling pathway.

show abstract

“…In addition to the efficacy of the drug, understanding the safety of the drug and the pharmacokinetic profile of the bioactive compounds in the drug is crucial for determining the potential for successful treatment [ 1 , 2 ]. Sanguisorba officinalis L. ( S. officinalis ), belonging to the Rosaceae family and Sanguisorba genus, has detoxification, analgesic [ 3 ], and hemostasis [ 4 ] functions, which are noted in the Chinese Pharmacopoeia (2020 edition). It also possesses antioxidative [ 5 ], anti-inflammation [ 6 ], antiviral [ 7 ], antibacterial [ 8 , 9 ], and anti-tumor effects [ 10 ], as well as having anti-proliferative effects against breast cancer [ 11 ], liver cancer [ 12 ], lung cancer [ 13 ], and colorectal cancer [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination and Pharmacokinetics Study of Three Triterpenes from Sanguisorba officinalis L. in Rats by UHPLC–MS/MS

Wei

Yang

et al. 2022

Molecules

View full text Add to dashboard Cite

A selective and rapid ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) method was established and validated for the determination of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, and pomolic acid in rats after the oral administration of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, pomolic acid, and Sanguisorba officinalis L. extract. The separation was carried out on an ACQUITY UPLC®HSS T3 column (2.1 mm × 100 mm, 1.8 μm), using methanol and 5 mmol/L ammonium acetate water as the mobile phase. The three compounds were quantified using the multiple reaction monitoring mode with the electrospray ion source in both the positive and negative mode. Liquid-liquid extraction was applied to the plasma sample preparation. Bifendate was selected as the internal standard. The intra-day and inter-day precision and the accuracy of the method were all within receivable ranges. The lower limit of quantification of ziyuglycoside I, 3β,19α-dihydroxyurs-12-en-28-oic-acid 28-β-d-glucopyranosyl ester, and pomolic acid were 6.50, 5.75, and 2.63 ng/mL, respectively. The extraction recoveries of analytes in rat plasma ranged from 83 to 94%. The three components could be rapidly absorbed into the blood (Tmax, 1.4–1.6 h) both in the single-administration group or S. officinalis extract group, but the first peak of PA occurred at 0.5 h and the second peak at 4–5 h in the S. officinalis extract. Three compounds were eliminated relatively slowly (t1/2, 7.3–11 h). The research was to establish a rapid, sensible, and sensitive UHPLC–MS/MS method using the multi-ion mode for multi-channel simultaneous mensuration pharmacokinetics parameters of three compounds in rats after oral administration of S. officinalis extract. This study found, for the first time, differences in the pharmacokinetic parameters of the three compounds in the monomer compounds and S. officinalis extract administration, which preliminarily revealed the transformation and metabolism of the three compounds in vivo.

show abstract

The Oral Administration of Sanguisorba officinalis Extract Improves Physical Performance through LDHA Modulation

Cited by 6 publications

References 78 publications

Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Sanguisorba officinalis L. promotes diabetic wound healing in rats through inflammation response mediated by macrophage

Simultaneous Determination and Pharmacokinetics Study of Three Triterpenes from Sanguisorba officinalis L. in Rats by UHPLC–MS/MS

Contact Info

Product

Resources

About